SynthesisFrontiers in pediatrics2024
Biomarkers in retinopathy of prematurity: a systematic review and meta-analysis.
Synthesis in Frontiers in pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Degree of thrombocytopenia and severity of retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Management of retinopathy of prematurity in a tertiary referral neonatal intensive care unit: Treatment rates and the impact of outsourcing laser therapy.Acta ophthalmologica · 2026Observational
- Risk factors for severe retinopathy of prematurity: A retrospective case-control study.Experimental and therapeutic medicine · 2026Article
- A Potential Gut-Retina Axis in Retinopathy of Prematurity: Emerging Perspectives on Microbiome-Mediated Modulation of the IGF-1-VEGF Pathway.International journal of molecular sciences · 2026Review
- Ocular surface inflammatory cytokines as a biomarker for retinopathy of prematurity.Eye (London, England) · 2026Article
- Early Nutritional Patterns and Metabolic Biomarkers Associated with ROP Severity.Medicina (Kaunas, Lithuania) · 2026Article
- Review of Retinopathy of Prematurity Management in the Anti-VEGF Era: Evolving Global Paradigms, Persistent Challenges and Our AI-Assisted Future.Clinical & experimental ophthalmology · 2025Review
- Involving neonatal hematology and transfusion medicine in global efforts to eliminate severe retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2025Review
- From Blood Count Parameters to ROP Risk: Early Hematological Predictors in Preterm Infants.Medicina (Kaunas, Lithuania) · 2025Article
- Ethical Biobanking in Extremely Preterm Infants: Lessons From the EPITOP Study.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Development of a scoring model integrating inflammatory markers for predicting ROP in preterm neonates.International ophthalmology · 2025Article
- Determinants of retinopathy and short-term neurological outcomes after cerebral malaria.Scientific reports · 2025Article
- Association of Neonatal Morbidities and Postnatal Growth Faltering in Preterm Neonates.Healthcare (Basel, Switzerland) · 2025Article
- Beyond anti-VEGF: expanding the therapeutic horizon and biomarker landscape in retinopathy of prematurity.Frontiers in pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Retinopathy of prematurity is a significant global cause of childhood blindness. This study aims to identify serum biomarkers that are associated with the development of ROP. Methods: A systematic review and meta-analysis was conducted using PRISMA guidelines. Three databases were searched (Pubmed, Scopus and Web of Science) from 2003 to March 2023. Only studies investigating serum biomarker levels in preterm infants (<37 weeks gestation) were included. Results: Meta-analysis suggests that low serum IGF-1 levels have a strong association with the development of ROP [SMD (95% CI) of -.46 [-.63, -.30], Conclusion: Low levels of serum IGF-1, high levels of serum glucose and thrombocytopenia all appear to have the strongest association with the development of ROP out of the 63 biomarkers investigated in this review. These associations highlight their potential use as diagnostic biomarkers in ROP, though further research is needed to establish the exact relationship between these biomarkers and disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.